Stock SPRINT SPRINT BIOSCIENCE AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Sprint Bioscience AB

Equities

SPRINT

SE0006343745

Market Closed - Nasdaq Stockholm
Other stock markets
 16:12:45 22/05/2024 BST 		5-day change 1st Jan Change
1.306 SEK -6.04% Intraday chart for Sprint Bioscience AB -2.10% -24.73%
05-08 Sprint Bioscience AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
02-14 Sprint Bioscience AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Given the positive cash flows generated by its business, the company's valuation level is an asset.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
SPRINT BIOSCIENCE AB Stock Sprint Bioscience AB
-24.73% 9.07M - -
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.80% 114B
B+
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.79% 107B
B+
BIONTECH SE Stock BioNTech SE
-5.61% 22.22B
B+
ARGENX SE Stock argenx SE
-0.67% 21.28B
B
GENMAB A/S Stock Genmab A/S
-4.64% 18.8B
A-
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.74% 17.51B
B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.36% 17.17B
A-
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.59% 14.14B
C+
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+34.86% 12.2B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
-
Finances

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. SPRINT Stock
  4. Ratings Sprint Bioscience AB